# US 2026/0115283 A1 · Method for treating cancer by using combination of asparagine inhibitor and immune checkpoint inhibitor and pharmaceutical composition comprising combination of asparagine inhibitor and immune checkpoint inhibitor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0115283 A1
- Document ID: US20260115283A1
- Status: Published application
- Kind: A1
- Application number: 19/219,665
- Filed: 2025-05-27
- Published: 2026-04-30
- Earliest claimed: 2024-05-28
- Assignees: Chang Gung Memorial Hospital, Linkou
- Applicants: Chang Gung Memorial Hospital, Linkou
- Inventors: Huang-Yu Yang; Ping-Chih Ho; Drew Mark Pardoll; Cheng-Ta Yang; Chun-Te Wu; See-Tong Pang; Cheng-Lung Hsu; Hsuan-Chia Chang; Chung-Ying Tsai
- Web page: https://patentgrep.com/patent/US20260115283A1

## CPC

- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 38/50: acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- C07K 16/2818: {against CD28 or CD152}
- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- C07K 16/40: against enzymes
- C12Y 305/01001: Asparaginase (3.5.1.1)
- A61K 2039/505: {comprising antibodies}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Y: ENZYMES

## Abstract

The present disclosure provides a method for treating cancer by using a combination of an asparagine inhibitor and an immune checkpoint inhibitor and a pharmaceutical composition including the combination of the asparagine inhibitor and the immune checkpoint inhibitor. The present disclosure achieves the effects of treating cancer through various efficacy experiments.

## Claims

### Claim 1

A method for treating cancer, comprising administering to a subject in need thereof a pharmaceutical composition comprising an effective amount of a combination of an asparagine inhibitor and an immune checkpoint inhibitor (ICI).

### Claim 2 (depends on 1)

The method according to claim 1, wherein the cancer is bladder carcinoma, breast cancer, glioblastoma, nasopharyngeal carcinoma, lung cancer, colorectal cancer, liver cancer, urothelial cancer, pancreatic cancer, renal cell carcinoma, prostate cancer, oral cancer, or melanoma.

### Claim 3 (depends on 2)

The method according to claim 2, wherein the nasopharyngeal carcinoma is recurrent-metastatic nasopharyngeal carcinoma (RM-NPC).

### Claim 4 (depends on 1)

The method according to claim 1, wherein the asparagine inhibitor is L-asparaginase.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the immune checkpoint inhibitor is an anti-PD-1 monoclonal antibody.

### Claim 6 (depends on 5)

The method according to claim 5, wherein the anti-PD-1 monoclonal antibody is pembrolizumab.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the combination of the asparagine inhibitor and the immune checkpoint inhibitor enhances efficacy of cancer immunotherapy by activating killer T cells.

### Claim 8 (depends on 7)

The method according to claim 7, wherein the killer T cells are CD8+ T cells.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the asparagine inhibitor has an asparagine deprivation effect.

### Claim 10 (depends on 9)

The method according to claim 9, wherein the asparagine deprivation enhances glutamine metabolism to enhance CD8+ T cell activation.

### Claim 11 (depends on 9)

The method according to claim 9, wherein the asparagine deprivation tailors differentiation and metabolic adaptation in a reactive oxygen species (ROS)-dependent manner.

### Claim 12 (depends on 9)

The method according to claim 9, wherein the asparagine deprivation enhances CD8+ T cell effector functions.

### Claim 13 (depends on 1)

The method according to claim 1, wherein the pharmaceutical composition is in a dosage form for oral administration.

### Claim 14 (depends on 1)

The method according to claim 1, wherein the pharmaceutical composition is in a dosage form for parenteral administration.

### Claim 15

A pharmaceutical composition for treating cancer, comprising a combination of an asparagine inhibitor and an immune checkpoint inhibitor (ICI).

### Claim 16 (depends on 15)

The pharmaceutical composition according to claim 15, wherein the asparagine inhibitor is L-asparaginase.

### Claim 17 (depends on 15)

The pharmaceutical composition according to claim 15, wherein the immune checkpoint inhibitor is an anti-PD-1 monoclonal antibody.

### Claim 18 (depends on 17)

The pharmaceutical composition according to claim 17, wherein the anti-PD-1 monoclonal antibody is pembrolizumab.
